Literature DB >> 28111475

Immunobiology of Ebola and Lassa virus infections.

Joseph B Prescott1, Andrea Marzi1, David Safronetz2,3, Shelly J Robertson1, Heinz Feldmann1,3, Sonja M Best1.   

Abstract

Two of the most important contemporary emerging viruses that affect human health in Africa are Ebola virus (EBOV) and Lassa virus (LASV). The 2013-2016 West African outbreak of EBOV was responsible for more than 11,000 deaths, primarily in Guinea, Sierra Leone and Liberia. LASV is constantly emerging in these and surrounding West African countries, with an estimate of more than 500,000 cases of Lassa fever, and approximately 5,000 deaths, annually. Both EBOV and LASV are zoonotic, and human infection often results in a severe haemorrhagic fever in both cases. However, the contribution of specific immune responses to disease differs between EBOV and LASV. This Review examines innate and adaptive immune responses to these viruses with the goal of delineating responses that are associated with protective versus pathogenic outcomes.

Entities:  

Mesh:

Year:  2017        PMID: 28111475     DOI: 10.1038/nri.2016.138

Source DB:  PubMed          Journal:  Nat Rev Immunol        ISSN: 1474-1733            Impact factor:   53.106


  138 in total

1.  Human dendritic cells infected with the nonpathogenic Mopeia virus induce stronger T-cell responses than those infected with Lassa virus.

Authors:  Delphine Pannetier; Stéphanie Reynard; Marion Russier; Alexandra Journeaux; Noël Tordo; Vincent Deubel; Sylvain Baize
Journal:  J Virol       Date:  2011-06-01       Impact factor: 5.103

2.  A C-terminal basic amino acid motif of Zaire ebolavirus VP35 is essential for type I interferon antagonism and displays high identity with the RNA-binding domain of another interferon antagonist, the NS1 protein of influenza A virus.

Authors:  Amy L Hartman; Jonathan S Towner; Stuart T Nichol
Journal:  Virology       Date:  2004-10-25       Impact factor: 3.616

3.  Phylogenetic analysis of the Arenaviridae: patterns of virus evolution and evidence for cospeciation between arenaviruses and their rodent hosts.

Authors:  M D Bowen; C J Peters; S T Nichol
Journal:  Mol Phylogenet Evol       Date:  1997-12       Impact factor: 4.286

4.  Lassa fever, a new virus disease of man from West Africa. I. Clinical description and pathological findings.

Authors:  J D Frame; J M Baldwin; D J Gocke; J M Troup
Journal:  Am J Trop Med Hyg       Date:  1970-07       Impact factor: 2.345

5.  Ebola hemorrhagic fever and pregnancy.

Authors:  K Mupapa; W Mukundu; M A Bwaka; M Kipasa; A De Roo; K Kuvula; K Kibadi; M Massamba; D Ndaberey; R Colebunders; J J Muyembe-Tamfum
Journal:  J Infect Dis       Date:  1999-02       Impact factor: 5.226

6.  Virion-associated phosphatidylethanolamine promotes TIM1-mediated infection by Ebola, dengue, and West Nile viruses.

Authors:  Audrey Stéphanie Richard; Adam Zhang; Sun-Jin Park; Michael Farzan; Min Zong; Hyeryun Choe
Journal:  Proc Natl Acad Sci U S A       Date:  2015-11-02       Impact factor: 11.205

7.  Therapeutic intervention of Ebola virus infection in rhesus macaques with the MB-003 monoclonal antibody cocktail.

Authors:  James Pettitt; Larry Zeitlin; Do H Kim; Cara Working; Joshua C Johnson; Ognian Bohorov; Barry Bratcher; Ernie Hiatt; Steven D Hume; Ashley K Johnson; Josh Morton; Michael H Pauly; Kevin J Whaley; Michael F Ingram; Ashley Zovanyi; Megan Heinrich; Ashley Piper; Justine Zelko; Gene G Olinger
Journal:  Sci Transl Med       Date:  2013-08-21       Impact factor: 17.956

8.  Pro- and anti-apoptotic CD95 signaling in T cells.

Authors:  Maren Paulsen; Ottmar Janssen
Journal:  Cell Commun Signal       Date:  2011-04-08       Impact factor: 5.712

9.  Two types of mouse T helper cell. IV. Th2 clones secrete a factor that inhibits cytokine production by Th1 clones.

Authors:  D F Fiorentino; M W Bond; T R Mosmann
Journal:  J Exp Med       Date:  1989-12-01       Impact factor: 14.307

10.  Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp.

Authors:  Xiangguo Qiu; Gary Wong; Jonathan Audet; Alexander Bello; Lisa Fernando; Judie B Alimonti; Hugues Fausther-Bovendo; Haiyan Wei; Jenna Aviles; Ernie Hiatt; Ashley Johnson; Josh Morton; Kelsi Swope; Ognian Bohorov; Natasha Bohorova; Charles Goodman; Do Kim; Michael H Pauly; Jesus Velasco; James Pettitt; Gene G Olinger; Kevin Whaley; Bianli Xu; James E Strong; Larry Zeitlin; Gary P Kobinger
Journal:  Nature       Date:  2014-08-29       Impact factor: 49.962

View more
  41 in total

1.  Persistence of Lassa Virus Associated With Severe Systemic Arteritis in Convalescing Guinea Pigs (Cavia porcellus).

Authors:  David X Liu; Donna L Perry; Lisa Evans DeWald; Yingyun Cai; Katie R Hagen; Timothy K Cooper; Louis M Huzella; Randy Hart; Amanda Bonilla; John G Bernbaum; Krisztina B Janosko; Ricky Adams; Reed F Johnson; Jens H Kuhn; Matthias J Schnell; Ian Crozier; Peter B Jahrling; Juan C de la Torre
Journal:  J Infect Dis       Date:  2019-05-05       Impact factor: 5.226

2.  A Systems Approach Reveals MAVS Signaling in Myeloid Cells as Critical for Resistance to Ebola Virus in Murine Models of Infection.

Authors:  Mukta Dutta; Shelly J Robertson; Atsushi Okumura; Dana P Scott; Jean Chang; Jeffrey M Weiss; Gail L Sturdevant; Friederike Feldmann; Elaine Haddock; Abhilash I Chiramel; Sanket S Ponia; Jonathan D Dougherty; Michael G Katze; Angela L Rasmussen; Sonja M Best
Journal:  Cell Rep       Date:  2017-01-17       Impact factor: 9.423

Review 3.  Human immune system mouse models of Ebola virus infection.

Authors:  Jessica R Spengler; Joseph Prescott; Heinz Feldmann; Christina F Spiropoulou
Journal:  Curr Opin Virol       Date:  2017-08-12       Impact factor: 7.090

4.  Role of Transmembrane Protein 16F in the Incorporation of Phosphatidylserine Into Budding Ebola Virus Virions.

Authors:  Patrick Younan; Mathieu Iampietro; Rodrigo I Santos; Palaniappan Ramanathan; Vsevolod L Popov; Alexander Bukreyev
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

Review 5.  Post-exposure treatments for Ebola and Marburg virus infections.

Authors:  Robert W Cross; Chad E Mire; Heinz Feldmann; Thomas W Geisbert
Journal:  Nat Rev Drug Discov       Date:  2018-01-29       Impact factor: 84.694

6.  Adenoviral vector-based vaccine is fully protective against lethal Lassa fever challenge in Hartley guinea pigs.

Authors:  Junki Maruyama; Elizabeth J Mateer; John T Manning; Rachel Sattler; Alexey V Seregin; Natalya Bukreyeva; Frank R Jones; Joseph P Balint; Elizabeth S Gabitzsch; Cheng Huang; Slobodan Paessler
Journal:  Vaccine       Date:  2019-09-24       Impact factor: 3.641

7.  Ebola Virus Shed Glycoprotein Triggers Differentiation, Infection, and Death of Monocytes Through Toll-Like Receptor 4 Activation.

Authors:  Mathieu Iampietro; Rodrigo I Santos; Ndongala Michel Lubaki; Alexander Bukreyev
Journal:  J Infect Dis       Date:  2018-11-22       Impact factor: 5.226

8.  Integrated pathogen load and dual transcriptome analysis of systemic host-pathogen interactions in severe malaria.

Authors:  Hyun Jae Lee; Athina Georgiadou; Michael Walther; Davis Nwakanma; Lindsay B Stewart; Michael Levin; Thomas D Otto; David J Conway; Lachlan J Coin; Aubrey J Cunnington
Journal:  Sci Transl Med       Date:  2018-06-27       Impact factor: 17.956

9.  Ebola Virus Requires Phosphatidylserine Scrambling Activity for Efficient Budding and Optimal Infectivity.

Authors:  Marissa D Acciani; Maria F Lay Mendoza; Katherine E Havranek; Avery M Duncan; Hersha Iyer; Olivia L Linn; Melinda A Brindley
Journal:  J Virol       Date:  2021-07-28       Impact factor: 5.103

Review 10.  Ebola virus disease: an update on post-exposure prophylaxis.

Authors:  William A Fischer; Pauline Vetter; Daniel G Bausch; Timothy Burgess; Richard T Davey; Robert Fowler; Frederick G Hayden; Peter B Jahrling; Andre C Kalil; Douglas L Mayers; Aneesh K Mehta; Timothy M Uyeki; Michael Jacobs
Journal:  Lancet Infect Dis       Date:  2017-11-15       Impact factor: 25.071

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.